Previous 10 | Next 10 |
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmac...
Adamis Pharmaceuticals ( ADMP ) announced that it still has “not received any notice of action” from the FDA regarding ZIMHI’s NDA. The FDA set ZIMHI’s PDUFA date for October 31 st , but it looks like the FDA is running a bit behind schedule. I have to applaud the...
SAN DIEGO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Tuesday, November 12, 2019 at 2:00 pm Pacific Time to discuss its financial and operat...
SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that as of the close of business today, Adamis has not received any notice of action from the U.S. Food and Drug Administration (“FDA”) o...
Adamis Pharmaceuticals ( ADMP ) has an FDA PDUFA date on October 31st regarding its naloxone product candidate, ZIMHI. After months of a slow bleed, the share price appears to have busted out of its downward channel and is showing signs of a PDUFA run-up. As we approach the PDUFA date, I expec...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch to s...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SAN DIEGO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the presentation of data pertaining to its investigational high dose naloxone product (ZIMHI) at the Institute of Human Virology (IHV) meeting (http://...
Adamis Pharmaceuticals ( ADMP ) recently released a couple of positive updates regarding their SYMEPI and ZIMHI products. Despite both press releases being positive, the market smashed the share price down to fresh 52-week lows. Investors aren't biting on these updates and appear to be waiting...
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty (“Emerge”) to register and commercialize Adamis’ ...
News, Short Squeeze, Breakout and More Instantly...
Adamis Pharmaceuticals Corporation Company Name:
ADMP Stock Symbol:
NASDAQ Market:
Adamis Pharmaceuticals Corporation Website:
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing sm...
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 ...
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in...